LT-α has been recently shown to be a contributor to TNF-α-independent intestinal damage in preclinical models, potentially explaining the proportion of non-responders to anti-TNF-α therapy amongst human IBD patients [40]. The gene discussed is TNF; the disease is inflammatory bowel disease.